With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the ...

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Vertex VRTX obtained FDA approval for its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...